Founded in 1997, GPC Biotech focuses on discovering and developing novel anti-cancer drugs. Their product portfolio includes Satraplatin, MAb 1D09C3, and RGB-286199. In 2000, they acquired Mitotix, Inc., a US-based drug discovery company. GPC Biotech went public in 2000 and merged with Agennix Inc. in 2009. Headquartered in Germany, they have a subsidiary in New Jersey.